MX2023006677A - Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). - Google Patents

Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme).

Info

Publication number
MX2023006677A
MX2023006677A MX2023006677A MX2023006677A MX2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A
Authority
MX
Mexico
Prior art keywords
macular degeneration
amd
related macular
compositions
treating dry
Prior art date
Application number
MX2023006677A
Other languages
English (en)
Inventor
Anthony Caggiano
Susan Catalano
Mary Hamby
Nicholas Izzo
Gary Look
Gilbert Rishton
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of MX2023006677A publication Critical patent/MX2023006677A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con métodos para tratar la degeneración macular seca relacionada con la edad (DME seca), que comprende administrar a un sujeto que lo necesita, una cantidad terapéuticamente eficaz de un compuesto o una composición farmacéutica de acuerdo con cualquier realización descrita en la presente.
MX2023006677A 2020-12-11 2021-12-10 Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). MX2023006677A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063124695P 2020-12-11 2020-12-11
PCT/US2021/062850 WO2022125925A1 (en) 2020-12-11 2021-12-10 Compositions for treating dry age-related macular degeneration (amd)

Publications (1)

Publication Number Publication Date
MX2023006677A true MX2023006677A (es) 2023-06-27

Family

ID=81974688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006677A MX2023006677A (es) 2020-12-11 2021-12-10 Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme).

Country Status (10)

Country Link
US (1) US20240009168A1 (es)
EP (1) EP4259129A1 (es)
JP (1) JP2023553414A (es)
KR (1) KR20230118158A (es)
CN (1) CN116867488A (es)
AU (1) AU2021396380A1 (es)
CA (1) CA3200346A1 (es)
IL (1) IL303592A (es)
MX (1) MX2023006677A (es)
WO (1) WO2022125925A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3498692T3 (da) 2014-01-31 2022-05-16 Cognition Therapeutics Inc Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration
JP7218306B2 (ja) 2017-05-15 2023-02-06 コグニション セラピューティクス インク． 神経変性疾患を治療するための組成物
ES2969373A1 (es) 2022-10-14 2024-05-17 Igen Biolab Group Ag Composicion obtenida de lisados de microorganismos probioticos para uso en el tratamiento y/o prevencion de las enfermedades degenerativas del ojo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020483A1 (en) * 2003-06-12 2005-01-27 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
US7829562B2 (en) * 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
US20110269779A1 (en) * 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
DK3498692T3 (da) * 2014-01-31 2022-05-16 Cognition Therapeutics Inc Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration
JP7218306B2 (ja) * 2017-05-15 2023-02-06 コグニション セラピューティクス インク． 神経変性疾患を治療するための組成物

Also Published As

Publication number Publication date
WO2022125925A1 (en) 2022-06-16
EP4259129A1 (en) 2023-10-18
JP2023553414A (ja) 2023-12-21
US20240009168A1 (en) 2024-01-11
AU2021396380A1 (en) 2023-06-22
IL303592A (en) 2023-08-01
KR20230118158A (ko) 2023-08-10
CN116867488A (zh) 2023-10-10
CA3200346A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
MX2023006677A (es) Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme).
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
MX2019012676A (es) Derivados de 2-aminoquinolina.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
PH12020500257A1 (en) Quinoline derivatives for treating infections with helminths
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
CR20210201A (es) Nuevos compuestos antihelmínticos
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MY168413A (en) Amino-substituted imidazopyridazines
PH12020500134A1 (en) Dihydrooxadiazinones
WO2020126968A3 (en) Urea derivatives for use against proliferative diseases
WO2017198341A8 (en) MACROCYCLIC INDOLE DERIVATIVES
PH12020551891A1 (en) New quinoline derivatives
MX2021001272A (es) Composiciones de bismuto-tiol y metodos de uso.
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
CR20230052A (es) Combinaciones para el tratamiento de cáncer.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
CR20230485A (es) Derivados de fósforo como nuevos inhibidores de sos1
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
EP4166156A4 (en) COMPOSITION FOR THE PREVENTION, MITIGATION OR TREATMENT OF ALLERGIC DISEASES OR PRURITUS WITH PENTAPEPTIDE AS THE ACTIVE INGREDIENT
PH12020551117A1 (en) Compositions for preventing or treating uveitis
PH12020551620A1 (en) Compositions for preventing or treating dry eye
MX2021015732A (es) Administracion intranasal de merotocina para mejorar la lactancia.
PH12020550549A1 (en) Compositions for preventing or treating lupus